- Home
- TMQ vs ADAG Comparison
TMQ vs ADAG Comparison
Compare TMQ & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- ADAG
- Stock Information
- Founded
- TMQ 2004
- ADAG 2011
- Country
- TMQ Canada
- ADAG China
- Employees
- TMQ N/A
- ADAG N/A
- Industry
- TMQ Precious Metals
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- TMQ Basic Materials
- ADAG Health Care
- Exchange
- TMQ Nasdaq
- ADAG Nasdaq
- Market Cap
- TMQ 83.6M
- ADAG 85.9M
- IPO Year
- TMQ N/A
- ADAG 2021
- Fundamental
- Price
- TMQ $1.20
- ADAG $1.84
- Analyst Decision
- TMQ
- ADAG Strong Buy
- Analyst Count
- TMQ 0
- ADAG 1
- Target Price
- TMQ N/A
- ADAG $5.00
- AVG Volume (30 Days)
- TMQ 224.1K
- ADAG 24.0K
- Earning Date
- TMQ 02-07-2025
- ADAG 03-09-2025
- Dividend Yield
- TMQ N/A
- ADAG N/A
- EPS Growth
- TMQ N/A
- ADAG N/A
- EPS
- TMQ N/A
- ADAG N/A
- Revenue
- TMQ N/A
- ADAG $815,746.00
- Revenue This Year
- TMQ N/A
- ADAG N/A
- Revenue Next Year
- TMQ N/A
- ADAG $2.70
- P/E Ratio
- TMQ N/A
- ADAG N/A
- Revenue Growth
- TMQ N/A
- ADAG N/A
- 52 Week Low
- TMQ $0.25
- ADAG $1.74
- 52 Week High
- TMQ $1.40
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- TMQ 57.45
- ADAG 40.33
- Support Level
- TMQ $1.10
- ADAG $1.76
- Resistance Level
- TMQ $1.24
- ADAG $2.07
- Average True Range (ATR)
- TMQ 0.06
- ADAG 0.14
- MACD
- TMQ -0.00
- ADAG -0.00
- Stochastic Oscillator
- TMQ 77.78
- ADAG 23.53
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-lead-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.